Published in Mov Disord on January 01, 2005
Rates of cerebral atrophy differ in different degenerative pathologies. Brain (2007) 1.90
Patterns of gray matter atrophy in atypical parkinsonism syndromes: a VBM meta-analysis. Brain Behav (2015) 0.86
18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy. Brain (2017) 0.81
In vivo evaluation of white matter pathology in patients of progressive supranuclear palsy using TBSS. Neuroradiology (2011) 0.79
Imaging biomarkers in Parkinson's disease and Parkinsonian syndromes: current and emerging concepts. Transl Neurodegener (2017) 0.75
The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord (2008) 5.72
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
Clinicopathological correlates in frontotemporal dementia. Ann Neurol (2004) 4.38
The pathological basis of semantic dementia. Brain (2005) 2.96
Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease. Brain (2014) 2.74
Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol (2009) 2.60
Pedigree with frontotemporal lobar degeneration--motor neuron disease and Tar DNA binding protein-43 positive neuropathology: genetic linkage to chromosome 9. BMC Neurol (2008) 2.34
FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol (2010) 2.30
Neuropathologic correlates of white matter hyperintensities. Neurology (2008) 2.29
GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. Ann Neurol (2005) 2.14
Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain (2013) 2.09
Multiple biological pathways link cognitive lifestyle to protection from dementia. Biol Psychiatry (2011) 1.79
In vivo identification of human cortical areas using high-resolution MRI: an approach to cerebral structure-function correlation. Proc Natl Acad Sci U S A (2003) 1.72
Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord (2014) 1.63
Cognitive, extrapyramidal, and magnetic resonance imaging predictors of functional impairment in nondemented older community dwellers: the Sydney Older Person Study. J Am Geriatr Soc (2006) 1.63
A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain (2005) 1.57
Small-vessel disease in patients with Parkinson's disease: a clinicopathological study. Mov Disord (2012) 1.56
Progression in frontotemporal dementia: identifying a benign behavioral variant by magnetic resonance imaging. Arch Neurol (2006) 1.47
Variability in neuronal expression of dopamine receptors and transporters in the substantia nigra. Mov Disord (2013) 1.44
Argyrophilic staining of nucleolar organizer region count and morphometry in benign and malignant melanocytic lesions. Am J Dermatopathol (2003) 1.44
C9ORF72 repeat expansion in clinical and neuropathologic frontotemporal dementia cohorts. Neurology (2012) 1.44
P25alpha immunoreactive but alpha-synuclein immunonegative neuronal inclusions in multiple system atrophy. Acta Neuropathol (2006) 1.43
Mutations in progranulin explain atypical phenotypes with variants in MAPT. Brain (2006) 1.43
Towards evidence-based dementia screening in Australia. Med J Aust (2011) 1.40
Cortical limb myoclonus in pathologically proven progressive supranuclear palsy. Mov Disord (2013) 1.39
Clinical significance of lobar atrophy in frontotemporal dementia: application of an MRI visual rating scale. Dement Geriatr Cogn Disord (2007) 1.39
Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. Brain (2002) 1.27
Monocyte chemoattractant protein-1 plays a dominant role in the chronic inflammation observed in Alzheimer's disease. Brain Pathol (2008) 1.26
Eating and hypothalamus changes in behavioral-variant frontotemporal dementia. Ann Neurol (2010) 1.24
Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models. Proc Natl Acad Sci U S A (2010) 1.24
Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degeneration-motor neuron disease. Ann Neurol (2010) 1.21
Presenilin-1 mutation L271V results in altered exon 8 splicing and Alzheimer's disease with non-cored plaques and no neuritic dystrophy. J Biol Chem (2002) 1.19
Regional and cellular pathology in frontotemporal dementia: relationship to stage of disease in cases with and without Pick bodies. Acta Neuropathol (2004) 1.19
α-Synucleinopathy phenotypes. Parkinsonism Relat Disord (2014) 1.16
Neuron loss from the hippocampus of Alzheimer's disease exceeds extracellular neurofibrillary tangle formation. Acta Neuropathol (2001) 1.12
Subcortical vascular disease and functional decline: a 6-year predictor study. J Am Geriatr Soc (2002) 1.11
Identifying the pattern of olfactory deficits in Parkinson disease using the brief smell identification test. Arch Neurol (2003) 1.10
Selective loss of pyramidal neurons in the pre-supplementary motor cortex in Parkinson's disease. Mov Disord (2002) 1.10
Postmortem analysis of bilateral subthalamic electrode implants in Parkinson's disease. Mov Disord (2002) 1.09
p25alpha relocalizes in oligodendroglia from myelin to cytoplasmic inclusions in multiple system atrophy. Am J Pathol (2007) 1.08
Severity of gliosis in Pick's disease and frontotemporal lobar degeneration: tau-positive glia differentiate these disorders. Brain (2003) 1.06
Visual misperceptions and hallucinations in Parkinson's disease: dysfunction of attentional control networks? Mov Disord (2011) 1.05
Binding deficits in memory following medial temporal lobe damage in patients with voltage-gated potassium channel complex antibody-associated limbic encephalitis. Brain (2013) 1.05
Human alcohol-related neuropathology. Acta Neuropathol (2013) 1.04
Reduced T helper and B lymphocytes in Parkinson's disease. J Neuroimmunol (2012) 1.03
Changes in the solubility and phosphorylation of α-synuclein over the course of Parkinson's disease. Acta Neuropathol (2011) 1.03
Distribution of brain atrophy in behavioral variant frontotemporal dementia. J Neurol Sci (2005) 1.02
Genetic and clinical features of progranulin-associated frontotemporal lobar degeneration. Arch Neurol (2011) 1.01
Understanding the pathogenesis of Alzheimer's disease: will RNA-Seq realize the promise of transcriptomics? J Neurochem (2011) 0.98
Staging of the cognitive decline in Alzheimer's disease: insights from a detailed neuropsychological investigation of mild cognitive impairment and mild Alzheimer's disease. Int J Geriatr Psychiatry (2011) 0.98
Tau-mediated nuclear depletion and cytoplasmic accumulation of SFPQ in Alzheimer's and Pick's disease. PLoS One (2012) 0.97
Do polymorphisms in the familial Parkinsonism genes contribute to risk for sporadic Parkinson's disease? Mov Disord (2009) 0.97
Lipid pathway alterations in Parkinson's disease primary visual cortex. PLoS One (2011) 0.96
Prevalence and clinical features of common LRRK2 mutations in Australians with Parkinson's disease. Mov Disord (2007) 0.95
Clinicopathological staging of frontotemporal dementia severity: correlation with regional atrophy. Dement Geriatr Cogn Disord (2004) 0.95
Mutations in the tau gene that cause an increase in three repeat tau and frontotemporal dementia. Brain (2003) 0.95
Degeneration in different parkinsonian syndromes relates to astrocyte type and astrocyte protein expression. J Neuropathol Exp Neurol (2009) 0.95
Variable phenotype of Alzheimer's disease with spastic paraparesis. J Neurochem (2007) 0.94
GIRK2 expression in dopamine neurons of the substantia nigra and ventral tegmental area. J Comp Neurol (2012) 0.94
Differences in regional brain atrophy in genetic forms of Alzheimer's disease. Neurobiol Aging (2006) 0.94
The role of dysfunctional attentional control networks in visual misperceptions in Parkinson's disease. Hum Brain Mapp (2013) 0.93
Focal demyelination in Alzheimer's disease and transgenic mouse models. Acta Neuropathol (2010) 0.93
A critical review of the development and importance of proteinaceous aggregates in animal models of Parkinson's disease: new insights into Lewy body formation. Parkinsonism Relat Disord (2004) 0.93
Dolichol is the major lipid component of human substantia nigra neuromelanin. J Neurochem (2005) 0.93
An improved high-throughput lipid extraction method for the analysis of human brain lipids. Lipids (2013) 0.92
Isoform-specific proteolysis of apolipoprotein-E in the brain. Neurobiol Aging (2009) 0.92
Unique transcriptome patterns of the white and grey matter corroborate structural and functional heterogeneity in the human frontal lobe. PLoS One (2013) 0.91
What is the dominant Abeta species in human brain tissue? A review. Neurotox Res (2005) 0.91
Low serum progranulin predicts the presence of mutations: a prospective study. J Alzheimers Dis (2010) 0.90
Pick bodies in a family with presenilin-1 Alzheimer's disease. Ann Neurol (2005) 0.90
Cortical atrophy differentiates Richardson's syndrome from the parkinsonian form of progressive supranuclear palsy. Mov Disord (2010) 0.89
Phosphorylation of soluble tau differs in Pick's disease and Alzheimer's disease brains. J Neural Transm (Vienna) (2009) 0.89
The case of a 48 year-old woman with bizarre and complex delusions. Nat Rev Neurol (2010) 0.89
Astrocytic degeneration relates to the severity of disease in frontotemporal dementia. Brain (2004) 0.89
Neurofilament-immunoreactive neurons in Alzheimer's disease and dementia with Lewy bodies. Neurobiol Dis (2002) 0.88
Selective hippocampal neuron loss in dementia with Lewy bodies. Ann Neurol (2002) 0.87
Positional effects of presenilin-1 mutations on tau phosphorylation in cortical plaques. Neurobiol Dis (2004) 0.87
Visual hallucinations in Parkinson's disease: theoretical models. Mov Disord (2014) 0.87
Cytoplasmic accumulation and aggregation of TDP-43 upon proteasome inhibition in cultured neurons. PLoS One (2011) 0.87
Macroautophagy in sporadic and the genetic form of Parkinson's disease with the A53T α-synuclein mutation. Transl Neurodegener (2012) 0.87
DNA methylation of the MAPT gene in Parkinson's disease cohorts and modulation by vitamin E in vitro. Mov Disord (2013) 0.86
Phosphorylation of apolipoprotein-E at an atypical protein kinase CK2 PSD/E site in vitro. Biochemistry (2005) 0.86